- TRADE NAME: Verzenio (Lilly)
- INDICATIONS: Hormone receptor-positive, human epidermal growth factor 2-negative advanced or metastatic breast cancer, either as monotherapy or in combination with fulvestrant; or as inital endocrine-based therapy with an aromatase inhibitor
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
- HALF-LIFE: 18 hours
- FDA APPROVAL DATE: 09/28/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Grapefruit Juice, Ketoconazole, Strong CYP3A4 inducers or inhibitors - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 05/15/2025
